8-K filing — CalciMedica, Inc. (CALC)
Filed: 2026-09-02 AccNo: 0001193125-26-379419 Size: 140 KB Item 8.01: Other Events
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
CalciMedica shares are trading lower after the company announced a 1-for-5 reverse stock split.
CalciMedica Announces 1-For-5 Reverse Stock Split, Effective August 28
CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for
Guggenheim Initiates Coverage On CalciMedica with Buy Rating, Announces Price Target of $9
Guggenheim analyst Vamil Divan initiates coverage on CalciMedica (NASDAQ:CALC) with a Buy rating and announces Price Target of $9.
National Civil Rights Museum Announces 35th Freedom Award Honorees
The National Civil Rights Museum announced the 2026 Freedom Award honorees, recognizing extraordinary contributions to civil and human rights. Recipients include attorney Fred D. Gray, Reverend Shavon Arline-Bradley, attorney Bakari Sellers, and WNBA champion Nneka Ogwumike. The 35th annual ceremony will be held October 1, 2026, at the Orpheum Theatre in Memphis, hosted by actor Larenz Tate and featuring a performance by gospel singer Tamela Mann.
This Under-the-Radar Dividend Stock Yields 6.2%. Is It a Buy?
UPS offers a high 6.2% dividend yield but faces sustainability concerns with a 91% forward payout ratio. While the company's turnaround efforts are progressing and analysts forecast 7% average earnings growth through 2029, dividend cut fears persist. The stock could appreciate to $140+ if valuations converge with competitors, making it potentially attractive for income investors willing to wait for the turnaround.